Your browser doesn't support javascript.
loading
Targeting Cdc42 in cancer.
Arias-Romero, Luis E; Chernoff, Jonathan.
Afiliação
  • Arias-Romero LE; Cancer Biology Program, Fox Chase Cancer Center , Philadelphia, PA , USA +1 215 728 5319 ; +1 215 728 3616 ; Jonathan.Chernoff@fccc.edu.
Expert Opin Ther Targets ; 17(11): 1263-73, 2013 Nov.
Article em En | MEDLINE | ID: mdl-23957315
INTRODUCTION: The Rho GTPases are a family of proteins that control fundamental cellular processes in response to extracellular stimuli and internal programs. Rho GTPases function as molecular switches in which the GTP-bound proteins are active and GDP-bound proteins are inactive. This article will focus on one Rho family member, Cdc42, which is overexpressed in a number of human cancers, and which might provide new therapeutic targets in malignancies. AREAS COVERED: In this article, the key regulators and effectors of Cdc42 and their molecular alterations are described. The complex interactions between the signaling cascades regulated by Cdc42 are also analyzed. EXPERT OPINION: While mutations in Cdc42 have not been reported in human cancer, aberrant expression of Cdc42 has been reported in a variety of tumor types and in some instances has been correlated with poor prognosis. Recently, it has been shown that Cdc42 activation by oncogenic Ras is crucial for Ras-mediated tumorigenesis, suggesting that targeting Cdc42 or its effectors might be useful in tumors harboring activating Ras mutations.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína cdc42 de Ligação ao GTP / Neoplasias Idioma: En Ano de publicação: 2013 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína cdc42 de Ligação ao GTP / Neoplasias Idioma: En Ano de publicação: 2013 Tipo de documento: Article